Anti-Müllerian hormone testing is useful for individualization of stimulation protocols in oocyte donors

Reproductive BioMedicine Online

Volumn 20, Issue 1, 2010, Pages 42-47

  Nakhuda, Gary S ^a   Douglas, Nataki C ^a   Thornton, Melvin H ^a   Guarnaccia, Michael M ^a   Lobo, Rogerio ^a   Sauer, Mark V ^a  

^a Centre for Women's Reproductive Care ^*  (United States)

Author keywords

Anti M llerian hormone; Donor IVF; In vitro fertilization; M llerian inhibiting substance; Oocyte donation; Ovarian reserve

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; ESTRADIOL; HUMAN MENOPAUSAL GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; NOVAREL; RECOMBINANT FOLLITROPIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HORMONE DETERMINATION; HORMONE SENSITIVITY; HUMAN; MAJOR CLINICAL STUDY; OOCYTE DONATION; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY FUNCTION; OVARY HYPERSTIMULATION; PREDICTIVE VALIDITY; PREGNANCY RATE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STIMULATION;

EID: 77149164775     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rbmo.2009.10.009     Document Type: Article

References (23)

1. Barnhart, K., Osheroff, J., 1999. We are overinterpreting the predictive value of serum follicle-stimulating hormone levels. Fertil. Steril. 72, 8-9.
2. Barreto Melo, M.A., Garrido, N., Alvarez, C, et al., 2009. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil. Steril. 91, 148-156.
3. Cohen, M.A., Lindheim, S.R., Sauer, M.V., 1999. Donor age is paramount to success in oocyte donation. Hum. Reprod. 14, 2755-2758.
4. Cook, C.L., Siow, Y., Brenner, A.G., Fallat, M.E., 2002. Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil. Steril. 77, 141-146.
5. de Vet, A., Laven, J.S., de Jong, F.H., et al., 2002. Antimullerian hormone serum levels: a putative marker for ovarian ageing. Fertil. Steril. 77, 357-362.
6. Ebner, T., Sommergruber, M., Moser, M., et al., 2006. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum. Reprod. 21, 2022-2026.
7. Esposito, M.A., Coutifaris, C, Barnhart, K.T., 2002. A moderately elevated day 3 FSH concentration has limited predictive value, especially in younger women. Hum. Reprod. 17, 118-123.
8. Faber, B.M., Mercan, R., Hamacher, P., et al., 1997. The impact of an egg donor's age and her prior fertility on recipient pregnancy outcome. Fertil. Steril. 68, 370-372.
9. Fallat, M.E., Siow, Y., Marra, M., et al., 1997. Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil. Steril. 67, 962-965.
10. Ficicioglu, C., Kutlu, T., Baglam, E., Bakacak, Z., 2006. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil. Steril. 85, 592-596.
11. Hazout, A., Bouchard, P., Seifer, D.B., et al., 2004. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or oestradiol. Fertil. Steril. 82, 1323-1329.
12. Hehenkamp, W.J., Looman, C.W., Themmen, A.P., et al., 2006. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J. Clin. Endocrinol. Metab. 91, 4057-4063.
13. Klein, J., Sauer, M.V., 2002. Oocyte donation. Best Pract. Res. 16, 277-291.
14. Lee, T.H., Liu, C.H., Huang, CC, et al., 2008. Serum anti-Mullerian hormone and oestradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum. Reprod. 23, 160-167.
15. Letterie, G., Marshall, L., Angle, M., 2005. The relationship of clinical response, oocyte number, and success in oocyte donor cycles. J. Assist. Reprod. Genet. 22, 115-117.
16. Nakhuda, G.S., Chu, M.C., Wang, J.G., et al., 2006. Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil. Steril. 85, 1541-1543.
17. Nakhuda, G.S., Sauer, M.V., Wang, J.G., et al., 2007. Mullerian inhibiting substance is an accurate marker of ovarian response in women of advanced reproductive age undergoing IVF. Reprod. BioMed. Online 14, 450-454.
18. Nelson, S.M., Yates, R.W., Fleming, R., 2007. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles - implications for individualization of therapy. Hum. Reprod. 22, 2414-2421.
19. Seifer, D.B., MacLaughlin, D.T., Christian, B.P., et al., 2002. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil. Steril. 77, 468-471.
20. Silberstein, T., MacLaughlin, D.T., Shai, I., et al., 2006. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum. Reprod. 21, 159-163.
21. Somunkiran, A., Yavuz, T., Yucel, O., Ozdemir, I., 2007. Anti-Mullerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 134, 196-201.
22. Tsepelidis, S., Devreker, F., Demeestere, I., et al., 2007. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum. Reprod. 22, 1837-1840.
23. van Rooij, I.A., Broekmans, F.J., te Velde, E.R., et al., 2002. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod. 17, 3065-3071.